DeCure for Pigmented paravenous retinochoroidal atrophy
DeCure's Rare AI scientist maps pigmented paravenous retinochoroidal atrophy for drug repurposing — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. The community decides which DeCure goes to the lab first.
Disease modulePigmented paravenous retinochoroidal atrophy maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Drugs in the evidence
No approved-drug candidate for pigmented paravenous retinochoroidal atrophy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Optometry and Vision Science · 1993 · 12 citations
Pigmented Paravenous Retinochoroidal Atrophy
AbstractPigmented paravenous retinochoroidal atrophy is a rare disorder that is not well understood or classified. We examined a patient who had chorioretinal atrophy with pigment clusters located in the paravenous areas without macular involvement. Other conditions which may also present retinochoroidal atrophy and/or pigmentary degeneration are discussed. The electroretinography results were subnormal but the evoked potentials were not totally extinguished. Fluorescein angiography and retinography confirmed the relative and absolute scotomas corresponding to the atrophic paravenous areas.
Canadian journal of optometry/CJO. Canadian journal of optometry · 2024 · 1 citations · open access
An Uncommon Presentation of Pigmented Paravenous Retinochoroidal Atrophy
AbstractPigmented paravenous retinochoroidal atrophy is a rare diagnosis of exclusion as it can mimic many hereditary retinal (namely retinitis pigmentosa), infectious, and inflammatory disorders. Once diagnosed, it carries a favorable prognosis due to the macula being spared with slow to no progression and lack of symptoms. However, rare cases have noted macula involvement and symptoms including nyctalopia. Clinicians should be aware of presentations of pigmented paravenous retinochoroidal atrophy, beyond the typical findings noted in the literature, as these cases could be misdiagnosed. This case presents a rare presentation of pigmented paravenous retinochoroidal atrophy. A review of common and uncommon findings, potential pathophysiology, differential diagnoses, and multimodal imaging results is also presented.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a treatment exists. Committing $DECURE to a DeCure is a vote on research priority — it is not an investment, and confers no royalty, equity or IP ownership. Papers are published open-access.
